Table 4.
Initial ART regimens and risk of dropout
| Unadjusted analysis | Adjusted analysisb | |||
|---|---|---|---|---|
| Regimen backbonea | HR | P | AHR | P |
| AZT-based (reference) | - | - | - | - |
| TDF-based | 1.2 (1.0–1.4) | 0.022 | 1.4 (1.2–1.7) | <0.001 |
| D4T-based‡ | 1.3 (0.98–1.6) | 0.072 | 1.2 (0.92–1.5) | 0.180 |
aAZT-based regimens contain zidovudine (AZT), lamivudine (3TC), and either nevirapine (NVP) or efavirenz (EFV); TDF-based regimens contain tenofovir (TDF), 3TC or FTC, and either NVP or EFV; D4T-based regimens contain stavudine (D4T), 3TC, and either NVP or EFV
bAdjusted for age, sex, year of ART initiation, and CD4+ T-cell count and hemoglobin concentration at ART initiation